• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Ra Medical launches large registry trial for peripheral laser device

Ra Medical launches large registry trial for peripheral laser device

June 19, 2019 By Brad Perriello

Ra MedicalRa Medical (NYSE:RMED) said today that it launched a large registry study to follow patients treated with its laser device for restenosis in the peripheral arteries.

Carldbad, Calif.-based Ra Medical’s Dabra device uses laser radiation ablation to bore through blockages in affected arteries. It’s designed to minimize damage to the surrounding vessel tissue.

The 2,500-patient Results trial is designed to evaluate outcomes for patients treated for re-narrowing of the peripheral arteries after an initial procedure to remove the blockage. Patients are slated for two years of follow-up at six-month intervals, the company said

“Restenosis, or re-narrowing of an artery post-procedure, is a major problem for my patients,” principal investigator Dr. C.V. Ramana, of Oklahoma City’s NAADI Healthcare, said in prepared remarks. “In my experience, Dabra has provided a highly effective treatment, with minimal vascular trauma, which I believe leads to lower rates of restenosis and longer lasting results.”

“In my practice, we are seeing very positive clinical outcomes using Dabra,” added study chairman Dr. Rajesh Dave, of Camp Hill, Pa.’s Geisinger Holy Spirit Hospital. “The goal of this study is to demonstrate the lasting lumen patency achieved with this exciting new technology.”

“Our mission at Ra Medical Systems is to help physicians save patients’ limbs and lives,” CEO Dean Irwin said in a press release. “We believe the clinical study will demonstrate that patients do not have to return to their doctor to be re-treated for the same blockage, which benefits that patient and the healthcare system as a whole.”

Dabra won CE Mark approval in the European Union in October 2016 and landed 510(k) clearance from the FDA the following May. Ra Medical brought in more than $86 million in an initial public offering in October 2018.

Filed Under: Clinical Trials, Vascular Tagged With: Peripheral, Ra Medical

More recent news

  • NICE recommends Boston Scientific Farapulse pulsed field ablation tech
  • SS Innovations completes first robotic telesurgery for weight loss
  • Johnson & Johnson MedTech adds new CMO for its Electrophysiology business
  • Abbott earns Medicare win for TriClip TEER system
  • Judge says Johnson & Johnson Ethicon owes $76.6M to ChemImage after failed partnership

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy